Following greater understanding of the multiple tumor immune escape mechanisms in recent years, programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) pathway inhibition, followed by immune system tumor killing effect reactivation has become a new strategy for treating cancer [6–7]. The gene discussed is CD274; the disease is neoplasm.